Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
89.47
+2.06 (2.36%)
At close: Dec 5, 2025, 4:00 PM EST
90.06
+0.59 (0.66%)
After-hours: Dec 5, 2025, 7:32 PM EST
Inhibrx Biosciences Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
| Revenue | 1.4 | 0.2 | 1.8 | 1.32 |
| Revenue Growth (YoY) | -19.26% | -88.89% | 36.88% | - |
| Cost of Revenue | 146.95 | 203.74 | 191.64 | 101.6 |
| Gross Profit | -145.55 | -203.54 | -189.84 | -100.29 |
| Selling, General & Admin | 49.58 | 59.84 | 29.35 | 15.04 |
| Operating Expenses | 49.58 | 59.84 | 29.35 | 15.04 |
| Operating Income | -195.13 | -263.39 | -219.19 | -115.32 |
| Interest Expense | -9.01 | -13.49 | -31.84 | - |
| Interest & Investment Income | 8.24 | 10.94 | 11.92 | - |
| Earnings From Equity Investments | - | - | -1.63 | - |
| Other Non Operating Income (Expenses) | -0.28 | 0.08 | -0.58 | 0 |
| EBT Excluding Unusual Items | -196.18 | -265.86 | -241.32 | -115.32 |
| Merger & Restructuring Charges | 41.1 | -68.06 | -0.04 | - |
| Other Unusual Items | - | 2,021 | - | - |
| Pretax Income | -155.08 | 1,688 | -241.36 | -115.32 |
| Income Tax Expense | 0 | 0 | 0 | 0 |
| Net Income | -155.09 | 1,688 | -241.36 | -115.33 |
| Net Income to Common | -155.09 | 1,688 | -241.36 | -115.33 |
| Shares Outstanding (Basic) | 15 | 15 | 12 | 43 |
| Shares Outstanding (Diluted) | 15 | 15 | 12 | 43 |
| Shares Change (YoY) | 6.72% | 27.17% | -72.77% | - |
| EPS (Basic) | -10.02 | 114.01 | -20.48 | -2.67 |
| EPS (Diluted) | -10.03 | 112.62 | -20.48 | -2.67 |
| Free Cash Flow | -143.44 | -197.01 | -197.9 | -91.5 |
| Free Cash Flow Per Share | -9.27 | -13.15 | -16.80 | -2.12 |
| Operating Margin | -13937.86% | -131693.50% | -12176.94% | -8769.81% |
| Profit Margin | -11077.57% | 843786.00% | -13408.94% | -8769.96% |
| Free Cash Flow Margin | -10245.64% | -98503.00% | -10994.56% | -6957.95% |
| EBITDA | -192.52 | -261.1 | -217.99 | -114.1 |
| D&A For EBITDA | 2.61 | 2.29 | 1.19 | 1.23 |
| EBIT | -195.13 | -263.39 | -219.19 | -115.32 |
| Revenue as Reported | 1.4 | 0.2 | 1.8 | 1.32 |
Source: S&P Capital IQ. Standard template.
Financial Sources.